MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.

AlphaQuest LLC increased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 969.6% in the 4th quarter ...

inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. Receive News & Ratings for Mirum Pharmaceuticals ...

It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally.

On the 1st postoperative day jaundice developed without pruritus or hepatosplenomegaly ... which were primarily the classic morphologic signs of cholestasis: dilated canaliculi in the centers ...

Symptoms include debilitating fatigue and itching (pruritus). PBC can worsen over ... patients on an 80 mg dose of elafibranor achieved a cholestasis response, measured using a biomarker of ...

Soon-to-be medical school graduates received 877 more primary care position offers in the 2025 Main Residency Match compared with the previous year, according to the National Resident Matching ...